Oricell Therapeutics to Showcase Innovations in Cell Therapies for oncology at 42nd JP Morgan Healthcare Conference

Oricell Therapeutics

Committed to Developing Novel Immunotherapies

Published Jan 1, 2024

Shanghai, China, and New Jersey, USA – January 1, 2024: Oricell Therapeutics (“Oricell” or the "Company"), a global clinical-stage biopharmaceutical firm dedicated to innovative cell therapies for oncology, is set to make its presence felt at the 42nd Annual JP Morgan Healthcare Conference. Co-founder and Chief Executive Officer, Ms. Helen Yang, and co-founder and Chief Scientific Officer, Dr. Peter He, will jointly participate in the conference.

During the event, we will share insights on the company's latest advancements in the field.

Presentation Date: January 10, 2024.

Presentation Time: 4:00 pm - 4:25 pm Pacific time.

Presentation Venue: San Francisco Marriott Marquis Golden Gate.

To view or add a comment, sign in

$Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma$

Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma

Jul 15, 2024
Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

Jun 5, 2024
Oricell to Present OriCAR-017 Data at 2024 ASCO Annual Meeting: Oral presentation of long-term follow-up data of GPRC5D CAR-T in RRMM

May 23, 2024
Oricell Therapeutics Announces Oral Presentation of OriCAR-017 Long-Term Follow-Up Data at the ASCO 2024 Annual Meeting

May 16, 2024
Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell for the treatment of RRMM

Jan 29, 2024
Oricell Presented at 42nd Annual J.P. Morgan Healthcare Conference

Jan 12, 2024
Oricell to showcase 4 Scientific Posters at SITC 2023 Annual Meeting

Oct 8, 2023
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

Aug 10, 2023
Oricell Therapeutics' donation initiative raises over ¥200,000 for employee’s family in medical emergency

Apr 21, 2023
Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

Feb 28, 2023

Insights from the community

Biotechnology

How can biopharmaceutical production be optimized for rare diseases?
Market Access

How can orphan drug developers use digital technologies and innovative solutions to enhance market access?
Statistics

How can statisticians contribute to the development of new drugs?
Chemical Engineering

How can you purify biopharmaceuticals more effectively?
Laboratory Management

How can you validate PCR assays for clinical or diagnostic applications?
Market Access

What are the main challenges and opportunities for orphan drug launch and lifecycle management?
Chemical Engineering

What is the best way to predict the pharmacokinetics of a drug?

Others also viewed

PD-1 Inhibitors: a New Class of Anticancer Agents Hits the Market

Charlotte Jago 9y
Liquid Biopsy at MolecularMD

Patrick Jackle 9y
2 projects awarded with the Nanomedicine Award 2015

Nicolas Gouze 8y
Top cancer drugs in 2015

Praveen D 8y
FDA OKs first generic version of Novartis' blockbuster leukemia pill Gleevec

Linda A. Johnson 8y
Why there is an increasing demand of Cancer medicines?

Nitesh Kumar 7y
DNA-Therapeutics acquired by ONXEO. D-Bait development to continue under new ownership.

Marc Lemaitre 8y
OncBioMune Awarded Patent for ProscaVax in Japan

Everett Jolly 7y
Hengrui’s Anti-PD-1 Monoclonal Antibody Formally Approved; A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma

Julia Zhang 5y
Time of selective oncology drugs

Rosa García-Tizón 5y

Explore topics

Sales
Marketing
Business Administration
HR Management
Content Management
Engineering
Soft Skills
See All

Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy, OriCAR-017, Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma

Jul 15, 2024

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy

Jun 5, 2024

Oricell to Present OriCAR-017 Data at 2024 ASCO Annual Meeting: Oral presentation of long-term follow-up data of GPRC5D CAR-T in RRMM

May 23, 2024

Oricell Therapeutics Announces Oral Presentation of OriCAR-017 Long-Term Follow-Up Data at the ASCO 2024 Annual Meeting

May 16, 2024

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell for the treatment of RRMM

Jan 29, 2024

Oricell Presented at 42nd Annual J.P. Morgan Healthcare Conference

Jan 12, 2024

Oricell to showcase 4 Scientific Posters at SITC 2023 Annual Meeting

Oct 8, 2023

Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

Aug 10, 2023

Oricell Therapeutics' donation initiative raises over ¥200,000 for employee’s family in medical emergency

Apr 21, 2023

Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

Feb 28, 2023

Insights from the community

Others also viewed

PD-1 Inhibitors: a New Class of Anticancer Agents Hits the Market

Liquid Biopsy at MolecularMD

2 projects awarded with the Nanomedicine Award 2015

Top cancer drugs in 2015

FDA OKs first generic version of Novartis' blockbuster leukemia pill Gleevec

Why there is an increasing demand of Cancer medicines?

DNA-Therapeutics acquired by ONXEO. D-Bait development to continue under new ownership.

OncBioMune Awarded Patent for ProscaVax in Japan

Hengrui’s Anti-PD-1 Monoclonal Antibody Formally Approved; A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma

Time of selective oncology drugs

Explore topics